PEC

Polymers Made from Emissions: The Plastics Industry May Become a Carbon-Capture Leader, says IDTechEx

Retrieved on: 
Tuesday, July 5, 2022
Carbon, Recycling, Polymer, Aviation biofuel, Consultant, Pressure, Protein, Electronics, Genetic engineering, Shoe, Climate change, PPC, OECD, Industry, Intellectual property, Carbon dioxide, PUR, Atmosphere, Subscription business model, CO2, Methane, Textile, Danone, Plastic, Ethanol, CCU, Technology, LPC, Newlight Technologies, PHB, PEC, Electrochemistry, Temperature, Methanol, Research, Polyurethane, Players, MEG, Coal, Petrochemical, Unilever, Mercedes-Benz Econic, Novomer, Covestro

As carbon dioxide (CO2) emissions also soar, the emerging carbon capture and utilization (CCU) industry propose a solution for both issues: creating lower-carbon, degradable polymers using CO2 emissions as the feedstock.

Key Points: 
  • As carbon dioxide (CO2) emissions also soar, the emerging carbon capture and utilization (CCU) industry propose a solution for both issues: creating lower-carbon, degradable polymers using CO2 emissions as the feedstock.
  • The recent IDTechEx report " Carbon Dioxide (CO2) Utilization 2022-2042: Technologies, Market Forecasts, and Players " analyzes the opportunities and challenges of creating this proposed circular carbon economy.
  • There are at least three major pathways to convert CO2 into polymers: electrochemistry, biological conversion, and thermocatalysis.
  • In the realm of emerging technologies, chemical precursors for CO2-based polymers can be obtained through electrochemistry or microbial synthesis.

Proactive news headlines including C29 Metals Ltd, Krakatoa Resources, Flynn Gold and Chimeric Therapeutics

Retrieved on: 
Tuesday, July 5, 2022
Magnet, Lithium, Well, KTA, GLOBE, ATC, Olympic Dam, RC, Clinical professor, LPI, AAU, REE, Humboldt Range, OTCQB, Golden, NOX, Baker Creek, KFM, PEC, Gold, RTR, Data management, JRL, AGC, Sempra Metals Ltd v IRC, Acquisition, OTCQX, SNS, LLL, ASX, Washington University in St. Louis, Proactivity, FFX, Pilbara Craton, DFS, IOCG, KOTH, Uranium, Sale, C29, Mayo Clinic, Antimony, Saindak Copper Gold Project, Program, Property management, Oil, Rare-earth element, Carretera Central (Cuba), Black Star Canyon

Click here

Key Points: 
  • Click here
    Krakatoa Resources Ltd (ASX:KTA) has wrapped up resource drilling at its 100%-owned Dalgaranga Critical Metals Project, around 70 kilometres from Mt Magnet in WA.
  • Click here
    Chimeric Therapeutics Ltd (ASX:CHM) has strengthened its management team with the appointment of experienced pharma executive Cassandra Harrison as vice president of Clinical Operations and Data Management.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

TripleBlind Wins Privacy Tech Award For Solving Data Privacy Challenges Through Privacy Enhancing Computation

Retrieved on: 
Thursday, June 30, 2022
Storm, Mayo Clinic, GLOBE, API, Accenture, General Catalyst, HIPAA, Compliance, Privacy, PET, Technology, PEC, GDPR, Rise, Method, Online shopping, Cryptocurrency

TripleBlind was recognized alongside seven other privacy technology startups, specifically for solving data privacy problems through PEC.

Key Points: 
  • TripleBlind was recognized alongside seven other privacy technology startups, specifically for solving data privacy problems through PEC.
  • Recipients were selected by The Rise of Privacy Tech (TROPT), an initiative meant to fuel the rise of privacy innovation by connecting privacy tech experts, investors and advocates.
  • Undisputed innovation abounds when real, sensitive data can be used for collaboration and analysis, and privacy enhancing computation enables that, said Storm.
  • We support all cloud platforms and unlock the intellectual property value of data, while preserving privacy and ensuring compliance with all known data privacy and data residency standards, such as HIPAA and GDPR.

TripleBlind Completes SOC 2® Type 1 Examination, Continues to Add Layers of Trust Through Third-Party Certifications

Retrieved on: 
Tuesday, June 7, 2022
Compliance, Privacy, Certified Public Accountant, Criterion, Time, PEC, Laika, Engineering, Confidentiality, American Institute of Certified Public Accountants, Senior, GLOBE, American Institute, Type 2, Certification, AICPA, SOC, NDA, SOC 2, Audit

By achieving SOC 2 Compliance, TripleBlind customers in the financial services and healthcare industries will benefit from added layers of trust including security, availability, processing, integrity, confidentiality and privacy.

Key Points: 
  • By achieving SOC 2 Compliance, TripleBlind customers in the financial services and healthcare industries will benefit from added layers of trust including security, availability, processing, integrity, confidentiality and privacy.
  • SOC 2 is an auditing procedure and report that examines an organizations internal controls for privacy and information security, assessing compliance at a specific point in time.
  • To earn this certification, TripleBlind worked closely with compliance-as-a-service platform Laika , which helps companies manage information security and privacy compliance, obtain security certifications and build trust with customers.
  • TripleBlind has already begun work with Laika on its SOC 2 Type 2 examination and is expected to complete Type 2 testing later this year.

Proactive news headlines including Chase Mining Corporation, Moho Resources, Magnis Energy Technologies and Perpetual Resources

Retrieved on: 
Thursday, May 26, 2022
Lithium, Copper, Webhelp, RTR, Social responsibility, CRR, AIM, Tonka, MNS, DUN, AGC, Sandbox, Gibsons, DTM, MV Ocean Star Pacific, OTCQX, CML, ASX, PEC, Jumbuck, GLOBE, ESG, Proactivity, CGP, BRU, SVM, Lead, Patient, OTC, Eyre Peninsula, MZZ, Granite Flats, AVR, Gold, Rare-earth element, Mining, Risk management, Uranium, Oil, NSW, Chinook, Callisto

Click here

Key Points: 
  • Click here
    Moho Resources Ltd (ASX:MOH) has received firm commitments from sophisticated and professional investors to raise $974,562 through a placement of shares at an issue price of $0.033 each.
  • Click here
    Element 25 Ltd (ASX:E25) has shipped 35,002 tonnes of Butcherbird manganese concentrate from Port Hedland aboard the MV Aquamarine SW on 24 May 2022.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Proactive news headlines including Imugene Ltd, Nova Minerals, Emmerson Resources and Recce Pharmaceuticals

Retrieved on: 
Friday, May 20, 2022
Lithium, Canada Business Corporations Act, SHP, Proactivity, PCHL, Sport, Roth Capital Partners, Music, OTC, NVA, Clinical trial, Julimar, ASX, GRP, TSX, PEC, CRR, Safety, IMU, AVL, Technology, Snow, NFT, SPP, PGE, RCE, HIO, OTCQB, PRU, GLOBE, Security (finance), Rare-earth element, Risk management, Tennant Creek, NSW

Click here

Key Points: 
  • Click here
    South Harz Potash Ltd (ASX:SHP)'s current chairman, Ian Farmer, has been appointed to the role of acting executive chairman.
  • Click here
    Proactive is a unique tech-enabled platform providing companies globally with a comprehensive investor engagement solution across their business lifecycle.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

The TV Shield CEO Throws Football at TV and Celebrates 50 Country Milestone

Retrieved on: 
Tuesday, May 10, 2022
Nestlé Purina PetCare, Georgia Tech Cable Network, Whole Foods Market, Dust, Name, Football, TV, Protective Enclosures Company, Theft, Air gun, Water, Designing Spaces, Wendy's, Electronics, High, TGI Fridays, Maker, Apple TV, UCF, Stadium, Country, Southwest Airlines, CEO, Roku, News, Restaurant, PEC, Multimedia, Television, Toy, Subway, Shield

ALTAMONTE SPRINGS, Fla., May 10, 2022 /PRNewswire/ -- Protective Enclosures Company (makers of The TV Shield) released a video to celebrate selling products in 50 countries as of 2022. Protective Enclosures Company is known for pioneering cutting-edge TV and outdoor digital signage protection enclosures.

Key Points: 
  • Protective Enclosures Company (Makers of The TV Shield Outdoor TV Enclosure) Celebrates 50 Country Milestone with Video: Throws Football at TV, Shoots it with Pellet Gun, and More
    ALTAMONTE SPRINGS, Fla., May 10, 2022 /PRNewswire/ --Protective Enclosures Company (makers of The TV Shield) released a video to celebrate selling products in 50 countries as of 2022.
  • PEC CEO, Jarad King, throws a football at a TV, sprays it with water, and more in the celebratory 50 country milestone video.
  • This footage demonstrates The TV Shield protecting the TV from high impact.
  • The PEC 50 Country Milestone Video also highlights over a decade of notable moments including features on the news and TV shows like Designing Spaces and Bar Rescue.

BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights

Retrieved on: 
Monday, May 9, 2022
Drug development, MCRPC, Baozou Big News Events, Development, Algorithm, Safety, Caregiver, Adenocarcinoma, Artificial intelligence, ET, MDD, SEC, CEO, Technology, Investor, PAS, Forward-looking statement, Checkpoint, AD, Oak Tree, Pembrolizumab, Company, Phenotype, Schizophrenia, Patient, Clinical trial, Program, III, FDA, Bipolar II disorder, Industry, Dementia, PEC, Positive, Nursing, Therapy, Neuroscience, Private Securities Litigation Reform Act, EMA, Dexmedetomidine, Physician, Research, Drug discovery, Monroe Dunaway Anderson, Agitation, MD, Thought disorder, Metastasis, SCNC, Prostate cancer, Lists of diseases, Goal, Qatar Investment Authority, COVID-19, Nasdaq, GLOBE, European Medicines Agency, Webcast, Combination, Administration, Patent, Marketing, Medical device, Pharmaceutical industry

ET

Key Points: 
  • ET
    NEW HAVEN, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the first quarter ended March 31, 2022 and provided an update on key strategic initiatives.
  • Our recent achievements across our clinical, business, and commercial priorities, highlighted by our first FDA approval of IGALMI, have positioned us to realize our 2022 goals and beyond, said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics.
  • BioXcel Therapeutics will host a conference call and webcast May 9, 2022, at 8:30 a.m., ET, to discuss its first quarter 2022 financial results and provide an update on recent operational highlights.
  • BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.

TÜV Rheinland: "Snake" makes offshore production safer

Retrieved on: 
Thursday, May 5, 2022
ATEX, Corrosion, Steam, Safety, EUR, Association, O&G, Environment, Industry, Business development, District, Life, Technology, United Nations Global Compact, PEC, Risk, Printed circuit board

LITTLETON, Mass., May 5, 2022 /PRNewswire/ -- Experts from TÜV Rheinland have developed a new probe for inspecting corrosion of the offshore oil and gas wells. The inspection tool features a caterpillar track design, is over 1 meter long and is as agile as a snake. Unlike all previous inspection probes, the "PEC Snake" can penetrate through a 2-inch hole or a 2-inch side valve arm. The highly flexible probe easily enters through sharp bends and can still be moved into tight spots on offshore platforms, such as between the conductor and the surface casing.

Key Points: 
  • LITTLETON, Mass., May 5, 2022 /PRNewswire/ -- Experts from TV Rheinland have developed a new probe for inspecting corrosion of the offshore oil and gas wells.
  • "The inspection tool has successfully passed its field test in the North Sea and is now available for use on offshore oil and gas production platforms worldwide," said Sergey Putintsev, Managing Director at TV Rheinland.
  • "Thanks to the smaller access and longer probe cable, the new Sonovation device can be used in many types of offshore production operations around the world."
  • Since 2006, TV Rheinland has therefore been a member of the United Nations Global Compact to promote sustainability and combat corruption.

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

Retrieved on: 
Tuesday, May 3, 2022
Drug development, Forward-looking statement, PAS, AD, Private Securities Litigation Reform Act, Nasdaq, Failure, GLOBE, Dexmedetomidine, Algorithm, Company, Safety, Food, Physician, Schizophrenia, Drug discovery, Patient, Caregiver, Clinical trial, Program, III, FDA, Agitation, Annual report, Bipolar II disorder, Artificial intelligence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Thought disorder, Breakthrough therapy, Dementia, Ageing, Marketing, Sale, Disease, Prostate cancer, Lists of diseases, SEC, PEC, Positive, Nursing, Therapy, Pharmaceutical industry, HAVEN

NEW HAVEN, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the first patient has been dosed in the Phase 3 TRANQUILITY II study of BXCL501, the Company’s proprietary, orally dissolving thin film formulation of dexmedetomidine, for the acute treatment of agitation in patients with Alzheimer’s disease (AD). The pivotal Phase 3 TRANQUILITY program includes two studies, TRANQUILITY II and TRANQUILITY III, which are designed to evaluate the safety and efficacy of BXCL501 in adults 65 years and older in assisted living or residential facilities and nursing homes.

Key Points: 
  • Previously, BXCL501 was granted Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the acute treatment of agitation associated with dementia.
  • Initiated in December of 2021, TRANQUILITY II and III are pivotal Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with Alzheimers disease.
  • TRANQUILITY II and III are designed to maximize the opportunity of BXCL501 for the treatment of the full spectrum of agitation associated with AD.
  • BXCL501 is also being evaluated for the acute treatment of agitation associated with Alzheimers disease, and as an adjunctive treatment for major depressive disorder.